Editors
I. Lugowska
S. Misale
R. Califano
J.B.A.G. Haanen
Contributors
Chapter 1. Introduction to Precision Oncology
I. Lugowska. Early Phase Clinical Trials Unit, Maria Skłodowska-Curie National Research Institute of Oncology (MSCI), Warsaw, Poland
S. Misale. Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
R. Califano. Department of Medical Oncology, The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, UK
J.B.A.G. Haanen. Netherlands Cancer Institute, Amsterdam, Netherlands
Chapter 2. Molecular Techniques in Precision Oncology
M. Oczko-Wojciechowska, Department of Clinical and Molecular Genetics, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland.
E. Giovannetti, Department of Medical Oncology, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands; Fondazione Pisana per la Scienza, San Giuliano Terme, Pisa, Italy.
Chapter 3. Hallmarks of Cancer
M.E. Vázquez-Cruz. Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Santiago de Querétaro, Mexico.
P. Basurto-Lozada. Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Santiago de Querétaro, Mexico.
I. Simonin-Wilmer. Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Santiago de Querétaro, Mexico.
C.D. Robles-Espinoza. Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Santiago de Querétaro, Mexico; Cancer, Ageing and Somatic Mutation Group, Wellcome Sanger Institute, Hinxton, UK.
Chapter 4. Molecular Pathways
U. Nayar. Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Biochemistry and Molecular Biology, Johns Hopkins School of Public Health, Baltimore, MD, USA.
E. Toska. Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Biochemistry and Molecular Biology, Johns Hopkins School of Public Health, Baltimore, MD, USA.
Chapter 5. Targeted T Cell Therapies for Solid Tumours
T.T.P. Seijkens. The Netherlands Cancer Institute, Amsterdam, Netherlands
J.B.A.G. Haanen. The Netherlands Cancer Institute, Amsterdam, Netherlands
S. Klobuch. The Netherlands Cancer Institute, Amsterdam, Netherlands
Chapter 6. Hormonal Targets
A. Bosch. Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Skåne, Sweden; Department of Clinical Sciences, Division of Oncology, Lund University, Lund, Sweden
J.M. Cejalvo. Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain
Chapter 7. Gene Fusions
U. Malapelle. Department of Public Health, University of Naples Federico II, Naples, Italy
A. Russo. Department of Onco-Hematology, Papardo Hospital, Messina, Italy
P.C. Mack. Center for Thoracic Oncology at Tisch Cancer Institute, Mount Sinai Health System and Icahn School of Medicine at Mount Sinai, New York, NY, USA
F.R. Hirsch. Center for Thoracic Oncology at Tisch Cancer Institute, Mount Sinai Health System and Icahn School of Medicine at Mount Sinai, New York, NY, USA
C. Rolfo. Center for Thoracic Oncology at Tisch Cancer Institute, Mount Sinai Health System and Icahn School of Medicine at Mount Sinai, New York, NY, USA
Chapter 8. Molecular Markers in Clinical Practice
Z.C. Ajgal. Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France
O. Le Saux. Department of Medical Oncology, Centre Leon Berard, Lyon; Université Claude Bernard & LYRICAN (INCA-DGOS-INSERM 12563), Lyon, France; Centre de Recherche en Cancérologie de Lyon, UMR Inserm 1052, CNRS 5286, Centre Léon Bérard, Lyon, France
C. Le Tourneau. Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France; INSERM U900, Saint-Cloud, France; Faculty of Medicine, Paris-Saclay University, Montigny le Bretonneux, France
J.-Y. Blay. Department of Medical Oncology, Centre Leon Berard, Lyon; Université Claude Bernard & LYRICAN (INCA-DGOS-INSERM 12563), Lyon, France; Centre de Recherche en Cancérologie de Lyon, UMR Inserm 1052, CNRS 5286, Centre Léon Bérard, Lyon, France
M. Kamal. Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France
Chapter 9. Molecular Markers in (Early Phase) Clinical Trials
N. Dieckmann. Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany
B. Fletcher. Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany
S. Bauer. Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany
Chapter 10. Thoracic Malignancies
T.S.K. Mok. Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China
N. Singh. Lung Cancer Clinic, Nehru Hospital, Postgraduate Institute of Medical Education and Research (PGIMER), Sector 12, Chandigarh, India
Chapter 11. Breast Cancer
M. Gion. Ramon y Cajal University Hospital, Madrid, Spain
J.M. Perez-Garcia. International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain
J. Cortes. International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain
Chapter 12. Gastrointestinal Malignancies
J. Ros. Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy; Department of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
T. Macarulla. Department of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
J. Tabernero. Department of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
E. Elez. Department of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Chapter 13. Genitourinary Malignancies
U.M. Vogl. IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland
E. Compérat. Department of Pathology, Hôpital Tenon, Sorbonne University, Paris, France
S. Gillessen. IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
Chapter 14. Melanoma
E. Livingstone. Department of Dermatology, University Hospital, Essen, Germany
L. Zimmer. Department of Dermatology, University Hospital, Essen, Germany
D. Schadendorf. Department of Dermatology, University Hospital, Essen, Germany
Chapter 15. Head & Neck Tumours
S. Cavalieri. Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
L. Licitra. Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
Chapter 16. Targeted Therapies in Haematological Malignancies
F. Esposito. Policlinico Tor Vergata, PTV, Rome, Italy; Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland
M.C. Pirosa. Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland
A.A. Moccia. Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland
A. Stathis. Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland
Chapter 17. Targeted Therapies in Gynaecological Malignancies
H. O’Sullivan. Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK
S. Banerjee. Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK; Division of Clinical Studies, The Institute of Cancer Research, London, UK
Chapter 18. Mesenchymal Tumours
P. Rutkowski. Maria Sklodowska-Curie National Research Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland
S. Stacchiotti. Fondazione IRCCS Istituto Nazionale dei Tumori, Adult Mesenchymal Tumour and Rare Cancer Medical Oncology Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
K. Kozak. Maria Sklodowska-Curie National Research Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland
Chapter 19. Central Nervous System Malignancies
A.S. Berghoff. Division of Oncology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria
M. Preusser. Division of Oncology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria
Chapter 20. Toxicity management
S. Morganti. Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy
M. Repetto. Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy
E. Crimini. Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy
G. Curigliano. Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy
